Dexamethasone Injection 8mg/2mL

Dexamethasone Injection 8mg/2mL: What the Published Guidance Says

The resuscitation, antidote and critical-care injectables that a functioning emergency department cannot run without — most of them named directly on the WHO Model List.

Buyers usually settle three things before ordering Dexamethasone Injection 8mg/2mL: the pharmacopoeial monograph, the pack configuration, and the documents the destination authority will ask for.

• Anaphylaxis and acute allergy The Model List places epinephrine (adrenaline) among the medicines used in anaphylaxis, and carries dexamethasone injection 4 mg/mL in 1 mL ampoule as disodium phosphate salt for both antiallergic use and palliative care, as well as in the antiemetic section. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
• Pre-operative and emergency antimuscarinics Atropine appears twice on the Model List — as a pre-operative medication at 400 micrograms/mL and 1 mg/mL (sulfate) in 1 mL ampoule or vial, and among specific antidotes. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
• Dexamethasone is a multi-role hospital injectable Beyond allergy, the Model List carries dexamethasone injection in the antiemetic section, where it appears alongside metoclopramide and ondansetron. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)

These points are quoted because they shape how Dexamethasone Injection 8mg/2mL is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.

How Dexamethasone Injection 8mg/2mL Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Dexamethasone Injection 8mg/2mL is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

• Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
• Testing for microbial limits and preservative efficacy (multi-dose presentations)
• Testing for heavy metals and elemental impurities
• Testing for packaging integrity and seal testing
• Testing for description and identification
• Testing for assay of the active substance

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How Dexamethasone Injection 8mg/2mL Is Packed, Labelled and Shipped

• Pack size: 2mL amber glass ampoule or vial. Non-standard pack sizes can be quoted against your artwork.
• Storage: Store below 25°C, protected from light. Do not freeze. Keep container in outer carton until use..
• Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
• Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
• Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for Dexamethasone Injection 8mg/2mL

Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.

• Batch manufacturing and packaging records released for inspection on request during supplier audits.
• Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
• CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
• Site Master File and GMP certificate for the manufacturing workshops.
• Method validation, stability protocol and the shelf-life justification for the marketed pack.

This page describes Dexamethasone Injection 8mg/2mL as a product of the emergency and critical-care injectables named in the WHO Model List family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.